Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Some preclinical in vivo studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy. This is an interim report of an ongoing cohort study examining the association between pioglitazone therapy and the risk of bladder cancer in patients with diabetes. RESEARCH DESIGN AND METHODS: This study includes 193,099 patients in the Kaiser Permanente Northern California diabetes registry who were ≥40 years of age between 1997 and 2002. Those with prior bladder cancer were excluded. Ever use of each diabetes medication (defined as two or more prescriptions within 6 months) was treated as a time-dependent variable. Cox regression–generated hazard ratios (HRs) compared pioglitazone use with nonpioglitazone use adjusted for age, sex, race/ethnicity, diabetes medications, A1C, heart failure, household income, renal function, other bladder conditions, and smoking. RESULTS: The group treated with pioglitazone comprised 30,173 patients. There were 90 cases of bladder cancer among pioglitazone users and 791 cases of bladder cancer among nonpioglitazone users. Overall, ever use of pioglitazone was not associated with risk of bladder cancer (HR 1.2 [95% CI 0.9–1.5]), with similar results in men and women (test for interaction P = 0.8). However, in the a priori category of >24 months of therapy, there was an increased risk (1.4 [1.03–2.0]). Ninety-five percent of cancers diagnosed among pioglitazone users were detected at early stage. CONCLUSIONS: In this cohort of patients with diabetes, short-term use of pioglitazone was not associated with an increased incidence of bladder cancer, but use for more than 2 years was weakly associated with increased risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Observational research conducted in 2011 and 2012 suggested that pioglitazone may increase the risk of bladder cancer.46,47”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [46]
The cited source says what the claim attributes to it.
In the citing paper
“Of note, some data suggest an association between the use of pioglitazone and an increased risk of bladder cancer (191).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“Some research suggests that metformin use is associated with a reduced risk for various cancers (23,24); others have suggested that insulin use might increase the risk of cancer (24,25).”
BackgroundDiabetes and Cancer: A Consensus Report
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,055
Elstner, E., Müller, C., Koshizuka, K., Williamson, E. A., Park, D., Asou, H., Shintaku, P., Said, J. W., Heber, D., & Koeffler, H. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8806 · Cited by 805
Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D. M., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.237 · Cited by 653
Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., SAID, J. W., Holden, S. A., Miyoshi, I., & Koeffler, H. P. (1998) · PubMed · Cited by 589
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Govindarajan, R., Ratnasinghe, L., Simmons, D. L., Siegel, E. R., Midathada, M. V., Kim, L., Kim, P. J., Owens, R. J., & Lang, N. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2777 · Cited by 336
Cited by
Items 401–500 of 711
Role and application of hysterosalpingography and Fallopian tube recanalization.
Mallarini, G., & Saba, L. (2010) · PubMed · Cited by 10
Carbohydrate Metabolism in Kidney Disease and Kidney Failure
Ritz, E., Adamczak, M., & Więcek, A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-391934-2.00002-3 · Cited by 10
Tseng, C. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.07.087 · Cited by 9
Şekeroğlu, Z. A., Şekeroğlu, V., Yedier, S. K., İlkun, E., & Liou, L. S. (2021) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22424 · Cited by 9
Systematic Reviews to Ascertain the Safety of Diabetes Medications
Gionfriddo, M. R., Morey‐Vargas, O. L., Brito, J. P., Leppin, A. L., Murad, M. H., & Montori, V. M. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0478-0 · Cited by 9
Lin, S.-J., Lin, C.-Y., Yang, D.-R., Izumi, K., Yan, E., Niu, X., Chang, H., Miyamoto, H., Wang, N., Li, G., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.02.005 · Cited by 9
Fujibayashi, K., Hayashi, M., Yokokawa, H., & Naito, T. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0187-8 · Cited by 9
Aoki, C., Suzuki, K., Kuroda, H., Sagara, M., Shimizu, M., Kasai, K., & Aso, Y. (2017) · Institutional Repositories DataBase (IRDB) · doi:10.18999/nagjms.79.1.9 · Cited by 9
Drug Repurposing for Retinoblastoma: Recent Advances
Dandu, K., Kallamadi, P. R., Thakur, S. S., & Rao, C. M. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190119152706 · Cited by 9
Hsu, J. C., Cheng, C., Ross‐Degnan, D., Wagner, A. K., Zhang, F., Yang, Y. K., Liu, L.-L., Tai, H.-Y., Chen, K.-H., Yang, P.-W., et al. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3834 · Cited by 9
PPAR-γ agonist pioglitazone and the risks of malignancy among type2 diabetes mellitus patients
See, L., Wu, C.-Y., Tsai, C., Lee, C., Chen, J., Jenq, C., Chen, C., Chen, Y., Yen, C., & Yang, H. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02378-y · Cited by 8
Li, J., Qiao, J., Zhang, S., Zhong, J., Chen, K., Lin, Y. C., Li, Y., Jin, Y., Yao, Y., Zhai, A., et al. (2025) · European journal of medical research · doi:10.1186/s40001-025-02749-3 · Cited by 8
Diabetes: an Overview for Clinical Oncologists
Lee, Y.-N., & Chowdhury, T. A. (2020) · Clinical Oncology · doi:10.1016/j.clon.2020.03.012 · Cited by 8
Cancer biology in diabetes update: Focusing on antidiabetic drugs
Kawakita, E., & Kanasaki, K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14152 · Cited by 8
Pioglitazone: are rumours of its death exaggerated?
Gale, E. (2015) · Diabetic Medicine · doi:10.1111/dme.12708 · Cited by 8
Dashti, S., Latiff, L. A., Zulkefli, N. A. B. M., Baharom, A., Minhat, H. S., Hamid, H. A., Ismail, M., Esfehani, A. J., Bakar, A. S. A., & Sabri, N. A. I. B. (2017) · PubMed Central · Cited by 8
Kim, S., Jeon, J., Park, S. J., & Kim, M. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.625 · Cited by 8
Kumar, S. (2020) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2020.13.555868 · Cited by 8
Shankar, S. S., Shankar, R. R., Railkar, R. A., Beals, C. R., Steinberg, H. O., & Kelley, D. E. (2015) · Current Therapeutic Research · doi:10.1016/j.curtheres.2015.08.001 · Cited by 8
Assay of Pioglitazone HCL by Using UV Visible Spectrophotometer
Naveed, S., Ashraf, Z., & Mukhtar, T. (2015) · British Journal of Research · Cited by 8
Pioglitazone and risk of bladder cancer: clarification of the design of the French study
Perez, A. T. (2012) · Diabetologia · doi:10.1007/s00125-012-2767-y · Cited by 8
Pioglitazone and bladder cancer – Authors' reply
Erdmann, E., Dormandy, J., Massi‐Benedetti, M., & Spanheimer, R. G. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61664-4 · Cited by 8
Reassessment of pioglitazone and bladder cancer based on FAERS database
Chen, H.-Y., Zhao, H., Yang, J., Zhang, Q., Yan, M.-M., & Qiu, X. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2390000 · Cited by 7
Association between pioglitazone use and bladder cancer: A systematic review
Baddam, S., Banka, A., Divity, S., Sandesara, M. P., & Vityala, Y. (2024) · Bladder · doi:10.14440/bladder.2024.0039 · Cited by 7
Seguridad cardiovascular de los antidiabéticos no insulínicos. Posicionamiento científico SEMERGEN
Prieto-Díaz, M. Á., Samper, J. M. C., Cervantes, C. E., & Molinera, V. G. (2014) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.04.005 · Cited by 7
How Does Pioglitazone Prevent Progression of Impaired Glucose Tolerance to Diabetes?
GENUTH, S. M. (2013) · Diabetes · doi:10.2337/db13-1175 · Cited by 7
Tseng, C. (2022) · BMC Cancer · doi:10.1186/s12885-022-09660-8 · Cited by 7
Tseng, C. (2023) · Pharmaceuticals · doi:10.3390/ph16050679 · Cited by 7
Management of hyperglycaemia in type 2 diabetic patients with Chronic Kidney Disease
Coelho, S., Carrilho, P., & Inchaustegui, L. (2013) · Portuguese Journal of Nephrology & Hypertension · Cited by 7
Ryder, R. E. J. (2015) · Diabetic Medicine · doi:10.1111/dme.12736 · Cited by 7
The new antidiabetic agents in the firing line… safety reasons or witch hunt?
Nicolau, J., & Masmiquel, L. (2012) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2011.11.003 · Cited by 7
Pioglitazone and bladder cancer: the pros and cons.
Panikar, V. (2012) · PubMed · Cited by 7
Juvenile oral angiofibroma in a female.
Reddy, B. K., Isaac, V., Nayak, M., & Prabhu, S. R. (1979) · PubMed · Cited by 7
Schrijnders, D., de Bock, G. H., Houweling, S. T., van Hateren, K. J. J., Groenier, K. H., Johnson, J. A., Bilo, H. J. G., Kleefstra, N., & Landman, G. W. D. (2017) · BMC Cancer · doi:10.1186/s12885-017-3433-z · Cited by 7
Fibrates and Risk of Cancer in Tissues with High PPAR-α Concentration: A Nested Case–Control Study
Salvo, F., Bazin, F., Kostrzewa, A., Bandre, C., Robinson, P., Moore, N. D., Bégaud, B., & Pariente, A. (2014) · Drug Safety · doi:10.1007/s40264-014-0157-8 · Cited by 7
The Safety of Prescription Drugs
Sharfstein, J. M., & Kesselheim, A. S. (2015) · JAMA · doi:10.1001/jama.2015.7151 · Cited by 7
Diabetes therapy and cancer risk: Where do we stand when treating patients?
Sun, G. E. C., Kashyap, S. R., & Nasr, C. E. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13140 · Cited by 6
Uwai, Y., & Nabekura, T. (2024) · Drugs - Real World Outcomes · doi:10.1007/s40801-024-00417-2 · Cited by 6
Usage of pioglitazone at Medanta, the Medicity
Mithal, A., Kaur, P., Bansal, B., Mishra, S., Wasir, J. S., Jevalikar, G., & Mahendru, S. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.126588 · Cited by 6
Antifibrotic role of macrophage migration inhibitory factor: Discovery of an unexpected function
Thủy, L. T. T., Kawada, N., Groszmann, R. J., Iwakiri, Y., & Taddei, T. H. (2012) · Hepatology · doi:10.1002/hep.25605 · Cited by 6
PPAR γ Agonists and the Future for Insulin Sensitizers
Henry, R. R., Erickson, D., & Ciaraldi, T. P. (2012) · The British Journal of Diabetes · doi:10.1177/1474651412459202 · Cited by 6
Cheng, V., Reddam, A., Bhatia, A., Hur, M., Kirkwood, J. S., & Volz, D. C. (2021) · Current Research in Toxicology · doi:10.1016/j.crtox.2021.03.003 · Cited by 6
Cheng, V., & Volz, D. C. (2022) · Current Research in Toxicology · doi:10.1016/j.crtox.2022.100079 · Cited by 6
Is there any robust evidence showing that SGLT2 inhibitor predisposes to cancer?
Çöpür, S., Yıldız, A. B., Covic, A. C., & Kanbay, M. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14131 · Cited by 6
Herbst, L., Goebel, M., Bandholtz, S., Gust, R., & Kintscher, U. (2012) · ChemMedChem · doi:10.1002/cmdc.201200337 · Cited by 6
Fröhlich, E., & Wahl, R. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01491.x · Cited by 6
Morais, J. F., de Sant’Anna, J. R., Pereira, T. S., Franco, C. C. D. S., Mathias, P. C. D. F., & de Castro‐Prado, M. A. A. (2016) · Mutagenesis · doi:10.1093/mutage/gew003 · Cited by 6
Wpływ czynników środowiskowych na rozwój raka pęcherza moczowego
Długosz, A., Gąsior, J., & Guzik, A. (2015) · Nowotwory Journal of Oncology · doi:10.5603/njo.2015.0004 · Cited by 6
The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone
Inzucchi, S. E., & Furie, K. L. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12399 · Cited by 6
The role of microbial pathogens in cancer development: a potential guide to anticancer drugs
Okeleye, B. I., Okudoh, V. I., & Ntwampe, S. K. O. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819001-2.00023-1 · Cited by 6
Rebello, C. J., Coulter, A. A., Reaume, A. G., Cong, W.-N., Cusimano, L. A., & Greenway, F. L. (2021) · Pharmaceuticals · doi:10.3390/ph14111196 · Cited by 6
India suspends pioglitazone: Is it justified?
SADIKOT, S. M., & Ghosal, S. (2014) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2013.10.020 · Cited by 6
Effect of Ketoconazole on Lobeglitazone Pharmacokinetics in Korean Volunteers
Oh, E. S., Kim, C. O., Kim, K. H., Kim, Y. N., Kim, C., Lee, J. I., & Park, M. S. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.05.064 · Cited by 6
Drug therapies for HIV-related metabolic disorders
Lamarca, K., Sarasola, A. G., Vidal, F., & Domingo, P. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1187133 · Cited by 6
Large Clinical Trials and Registries—Clinical Research Institutes
Califf, R. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-849905-4.00028-9 · Cited by 5
Kemp, A., Mintzes, B. J., Morrow, R. L., Dormuth, C. R., Souverein, P. C., & Roughead, E. E. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5508 · Cited by 5
Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
Spellman, C. (2012) · PubMed · Cited by 5
Basic Concepts in Insulin Resistance and Diabetes Treatment
Bril, F., & Cusi, K. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-72475-1_3 · Cited by 5
Jadhav, S., Shivane, V. K., Lila, A., Bandgar, T., & Shah, N. (2014) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.138765 · Cited by 5
Paediatrics, insulin resistance and the kidney
Marlais, M., & Coward, R. J. (2014) · Pediatric Nephrology · doi:10.1007/s00467-014-2890-8 · Cited by 5
Romero, V., Peyton, C. C., Gray, I., Hemal, A. K., & Terlecki, R. P. (2014) · BMC Urology · doi:10.1186/1471-2490-14-10 · Cited by 5
Does Pioglitazone Increase the Risk of Bladder Cancer in Japanese Diabetic Patients?
Kaga, K. (2014) · Medical & Surgical Urology · doi:10.4172/2168-9857.1000147 · Cited by 5
Pioglitazone and bladder cancer
Warren, H. R., Raison, N. T. J., & Dasgupta, P. (2015) · British Journal of Urology · doi:10.1111/bju.13352 · Cited by 5
Biased Signaling and Conformational Dynamics in Nuclear Hormone Receptors
Flaveny, C. A., Solt, L. A., Kojetin, D. J., & Burris, T. P. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411460-9.00004-5 · Cited by 5
Pioglitazone and cardiovascular risk reduction: time for a second look?
Perdigoto, A. L., Young, L. H., & Inzucchi, S. E. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000110 · Cited by 5
Wang, J., Liang, Y.-W., Yeh, C.-C., Liu, C.-S., & Wang, C.-Y. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-018968 · Cited by 5
Mahatma, A., Santhosh Kumar, M., & Sonowal, A. (2014) · IOSR Journal of Dental and Medical Sciences · doi:10.9790/0853-13125118125 · Cited by 5
β-cyclodextrin Based Nano Gene Delivery Using Pharmaceutical Applications to Treat Wolfram Syndrome
Quintas, P. C., Al‐Salami, H., Pfaff, A. L., Li, D., & Kõks, S. (2022) · Therapeutic Delivery · doi:10.4155/tde-2022-0036 · Cited by 5
Zespół metaboliczny jako czynnik ryzyka niedokrwiennego udaru mózgu
Łukasik, M., & Kozubski, W. P. (2012) · Neurologia i Neurochirurgia Polska · doi:10.5114/ninp.2012.28915 · Cited by 5
Diabetes drugs and the incidence of solid cancers: a survey of the current evidence
Tuccori, M., Convertino, I., Galiulo, M. T., Marino, A., Capogrosso-Sansone, A., & Blandizzi, C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1361401 · Cited by 5
Balancing the risks and benefits for pioglitazone in type 2 diabetes
Johnson, J. A., & Colmers-Gray, I. N. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.08.005 · Cited by 5
Mansure, J. J., Nassim, R., Chevalier, S., Szymanski, K. M., Rocha, J., Aldousari, S. A., & Kassouf, W. (2013) · PLoS ONE · doi:10.1371/annotation/50295123-3bb7-4916-812c-fa4ea5f09130 · Cited by 5
The Link Between Diabetes and Cancer: Converging Mechanistic and Epidemiologic Evidence
Lipscombe, L. L., Ali, S., & Lega, I. C. (2026) · Diabetes · doi:10.2337/dbi26-0003 · Cited by 4
Hsieh, M., Hu, S.-Y., Liao, S.-H., Chang, C.-M., Hsieh, V. C., & How, C. (2021) · Emergency Medicine International · doi:10.1155/2021/4916777 · Cited by 4
Srivastav, V. K., & Tiwari, M. (2021) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.857 · Cited by 4
Dybbro, E., Vos, M. B., & Kohli, R. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.012 · Cited by 4
Thiazolidinediones-PPAR-γ Agonists; for the treatment of Type II Diabetes Mellitus
Rekha, S. S., Chandrashekhara., S., Bhat, V. N., Haritas, A., Dheerathi, T., & Shivani, K. N. L. (2024) · Journal Of Advanced Zoology · doi:10.53555/jaz.v45i1.3687 · Cited by 4
Litigation Seeking Access to Data From Ongoing Clinical Trials: A Threat to Clinical Research
Kernan, W. N., Viscoli, C. M., & Varughese, M. C. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.3248 · Cited by 4
Los nuevos antidiabéticos en el punto de mira… ¿razones de seguridad o caza de brujas?
Nicolau, J., & Masmiquel, L. (2011) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2011.11.002 · Cited by 4
A nationwide, population-based, case-control study
Chen, S., Tsan, Y., Chen, J., Hsieh, H.-I., Lee, C., Lin, H.-H., Wang, J., & Chen, P. (2012) · Cited by 4
Treating Type 2 Diabetes Mellitus
Herzlinger, S., & Abrahamson, M. J. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_44 · Cited by 4
Mohammed, E. D., Abdel‐Naim, A. B., Jin, K., Jiang, R., Wei, J., & Sun, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118615 · Cited by 4
Matsumura, T., Taketa, K., Shimoda, S., & Araki, E. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00182.x · Cited by 4
Effects of thiazolidinedione in patients with active bladder cancer
Li, R., Metcalfe, M., Ferguson, J. E., Mokkapati, S., Nogueras‐González, G. M., Dinney, C. P., Navai, N., McConkey, D. J., Sahai, S. K., & Kamat, A. M. (2017) · British Journal of Urology · doi:10.1111/bju.14009 · Cited by 4
Pharmacotherapy of Diabetes Focused on Stroke
Lyu, Y. S., Kim, J., & Kim, S.-Y. (2019) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2019.3.1 · Cited by 4
Brunetti, V. C., Yu, O. H. Y., Platt, R. W., & Filion, K. B. (2021) · Diabetic Medicine · doi:10.1111/dme.14603 · Cited by 4
Evaluation of Type 2 Diabetes Mellitus Medication Management and Control in Older Adults
Thompson, A. M., Griend, J. P. V., Linnebur, S. A., & Saseen, J. J. (2013) · The Consultant Pharmacist · doi:10.4140/tcp.n.2013.296 · Cited by 4
Song, S. O., Kim, K. J., & Lee, B. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.6.462 · Cited by 4
Prevention and Treatment of Obesity and Diabetes and their Related Complications
Song, M. K. (2014) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.s1-009 · Cited by 4
Management of type 2 Diabetes in patients with Chronic Kidney Disease
Bansal, B. (2017) · Archives of Clinical Nephrology · doi:10.17352/acn.000026 · Cited by 4
Pioglitazone: A prudent prescription
Kalra, S., Dhamija, P., & Sahay, R. K. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.111594 · Cited by 4
Pharmacological and Toxicological Advances in PPAR-Related Medicines
Kamijo, Y., Nicol, C. J. B., & Alexson, S. E. H. (2012) · PPAR Research · doi:10.1155/2012/940964 · Cited by 4
Mishra, S., Nigam, N., Kumar, S., Jalota, K., Archana, A., Ahmad, S. S., & Katiyar, P. (2024) · Journal of Pharmacognosy and Phytochemistry · doi:10.22271/phyto.2024.v13.i5b.15061 · Cited by 3
Metabolic dysregulation: Its role in diabetes mellitus and cancers
Dai, S., Li, J., Xia, J., Liu, Y., & Li, Y. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101461 · Cited by 3
PPARγ (peroxisome proliferator-activated receptor gamma) receptor in diabetes mellitus
Sood, R., Mourya, A. K., Kumar, A., & Jeengar, M. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29129-6.00010-5 · Cited by 3
Combination therapy in type 2 diabetes mellitus
Abdul‐Ghani, M. A., DeFronzo, R. A., & Eldor, R. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch46 · Cited by 3
Toward More Scientific Relevance in Carcinogenicity Testing
van der Laan, J. W., DeGeorge, J. J., Sistare, F. D., & Moggs, J. G. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-5950-7_5 · Cited by 3
Antidiabéticos orais. Como começar e combinar sem risco cardiovascular
Duarte, R. (2013) · Revista Portuguesa de Cardiologia · doi:10.1016/s0870-2551(13)70043-x · Cited by 3
Will PPAR-γ agonist therapy still have a role in diabetes management in 2013?
Grunberger, G. (2012) · Diabetes Management · doi:10.2217/dmt.12.81 · Cited by 3
Pioglitazone—when is a prescription drug safe?
Loke, Y. K., & Mattishent, K. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.237 · Cited by 3
Metadata
- Authors
- Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L.
- Affiliations
- University of Pennsylvania (US)
- Kaiser Permanente (US)
- Corresponding author
- Lewis, James D.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-03-21
- Volume
- 34
- Issue
- 4
- Pages
- 916-922
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3064051
- OpenAlex
- W2121264929
- Cited by
- 625
- References
- 24
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 10 · 2023: 10 · 2022: 19 · 2021: 18 · 2020: 25 · 2019: 21 · 2018: 29 · 2017: 35 · 2016: 55 · 2015: 58 · 2014: 79 · 2013: 90 · 2012: 119
- FWCI
- 42.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- pioglitazone, bladder cancer, diabetes mellitus, drug safety, cancer risk, treatment duration, thiazolidinediones, antidiabetic drugs, early-stage cancer detection
- MeSH terms
- Pioglitazone, Adult, Aged, Urinary Bladder Neoplasms, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Longitudinal Studies, Male, Middle Aged, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.